China Grand Pharmaceutical to Acquire 7.6% Stake in Telix

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING: ByteDance Targets July Launch of Upgraded AI Video Model; Embodied AI Startup Kunlunxing Lands Multibillion Yuan Raise; Europe Has a Lot to Learn From China About Electric Trucks, Volvo CTO Says

LATEST: Europe Has a Lot to Learn From China About Electric Trucks, Volvo CTO Says; Embodied AI Startup Kunlunxing Lands Multibillion Yuan Raise; ByteDance Targets July Launch of Upgraded AI Video Model; China’s Starlink Challenger Seeks Up to $2.2 Billion for Satellite Network Push; New Model Propels Zhipu AI’s Market Value to Record HK$1 Trillion; In AI Pitch, Alibaba Chairman Urges Europe to Look Beyond U.S. Tech; Cover Story: China’s AI Boom Is Rewiring Its Power Grid; In Depth: How AI Is Rewiring White-Collar Work in China; Chipmaker YMTC Cedes Control of Foundry Unit Ahead of Mega IPO; Chinese Startup Manifold AI Raises Fresh Funding as Investors Bet on ‘World Models’; Crealights Takes Step Closer to Hong Kong IPO as Data Center Boom Fuels Growth Prospects; Tencent Lets AI Agent Make Purchases Through WeChat Pay; Galaxea AI Chief Says China Could Lead Robotics Models Within Three Years; SiliconFlow Raises $294 Million as China’s AI Inference Demand Surges; Ant Revamps Alipay With AI Assistant in Biggest App Overhaul; New Model Sends Zhipu AI’s Stock Soaring; DJI, Insta360 File Competing U.S. Patent Lawsuits Over Camera Tech; Cover Story: When Employees Leave, Their AI Clones Carry on Working; AI Stocks Zhipu, MiniMax Slide as Lock-Up Expirations Near; Japan’s Chip Exports to China Surge as Bilateral Trade Rebounds

By Bloomberg / Nov 02, 2020 10:28 AM / Finance

Photo: VCG

China Grand Pharmaceutical and Healthcare Holdings Ltd. will spend $25 million for a 7.6% stake in Australian biotech firm Telix Pharmaceuticals Ltd.

The companies entered a licensing and co-development agreement with upfront and milestone payments of as much as $225 million, Hong Kong-based China Grand said in a statement to the city’s stock exchange.

The deal will also include royalty fees for licensed products. China Grand will get exclusive development, manufacturing and commercialization rights in China, Hong Kong, Macau and Taiwan for radionuclide-drug conjugates developed by Melbourne-based Telix.

China Grand also agreed to buy 100% of the equity of Beijing Puer Weiye Biotechnology Co. Ltd., which holds licenses for radioactive pharmaceutical production and trading.

Contact editor Marcus Ryder (marcusryder@caixin.com)

Share this article

Open WeChat and scan the QR code